|
Uniphar PLC on Tuesday said it is confident of hitting medium-term targets after predicting double-digit adjusted earnings growth in 2024. In a trading update for the year ended December, the Dublin-based healthcare services company said the business performed in line with expectations for 2024 at an earnings per share level, while delivering normalised free cashflow conversion above medium-term guidance. The group achieved over 8% growth in organic gross profit and 12% adjusted EPS growth in 2024, it said. In 2023, Uniphar reported gross profit of €390.0 million and adjusted EPS of 18.3 euro cents. Uniphar said it is well positioned to deliver organic gross profit growth across all divisions. Consistent with the group’s medium-term targets, it predicts double digit organic gross profit growth in 2025 in Uniphar Pharma, high single digit growth in Uniphar Medtech and low single digit growth in Uniphar Supply Chain & Retail. Uniphar said it is managing an ‘active pipeline’ of acquisition opportunities, seeing M&A as playing an important role in the firm’s growth strategy. Chief Executive Ger Rabbette said: ‘2024 was a great year for Uniphar, with all our divisions contributing to excellent organic growth. The results show the positive impact that our strategy is having on our ability to grow at pace organically. We have now delivered a 5-year EPS [compound annual growth rate] of over 15%. Based on our 2024 results, we are even more confident of reaching our €200 million [earnings before interest, tax, depreciation and amortisation] target over the medium-term, with at least 80% of our growth being organic.’ Shares in Uniphar were 3.4% higher at 184.00 pence each in London on Tuesday. Uniphar expects to publish its final results for the year ended December on February 25. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
